肝细胞癌组织COPB2基因水平变化及其临床意义探讨

doi:10.3969/j.issn.1672-5069.2021.01.030

Abstract

Abstract: Objective The aim of this study was to investigate the expression of coatomer protein complex subunit beta 2 (copb2) gene in cancerous tissues in patients with hepatocellular carcinoma (HCC) and its relationship with prognosis. Methods 113 patients with HCC underwent hepatectomy, and the COPB2 mRNA and its protein expression in cancerous and adjacent noncancerous tissues were detected by RT-PCR and Western bloting as well as immunohistochemistry. The multivariate Cox proportional risk regression model was established to analyze the independent risk factors affecting the prognosis of patients with HCC. Results The COPB2 mRNA in cancerous and noncancerous tissues were (1.32±0.40) and (0.47±0.14), significantly different between them(P=0.013), and the COPB2 protein expression were (1.35±0.56) and (0.44±0.12), also significantly different between them(P=0.035); the strong cancerous COPB2 expression was found in 45 patients(39.8%), while the weak or negative expression was found in 68 patients(60.2%); the expression of COPB2 was found much different in patients with or without HBV infection, with different serum AFP levels, different tumor foci, different tumor cell differentiation, and with or without tumor invasion (P＜0.05); 68 patients (59.8%) died in our series at the end of follow-up, with the survival time of (1047.0±167.7) days; the survial time in patients with strong cancerous COPB2 expression was (747.3±116.3) days, much shorter than(1673.7±213.5) days in patients with weak or negative COPB2 expression(P=0.001); the multivariate Cox proportional risk regression model showed that the cancerous COPB2 expression, serum AFP levels, tumor invasion and tumor foci were the independent risk factor for overall survival of patients with HCC.Conclusion The up-regulation of COPB2 expression in cancerous tissues in patients with HCC might hint the bad prognosis after hepatectomy, which warrants further investigation.

Key words: Hepatocellular carcinoma, Coatomer protein complex subunit beta 2, Tumor markers, Prognosis

Liu Zhen,Pan Guangdong,Zhou Zheng,et al. Expression of copb2 gene incancerous tissues in patients with hepatocellular carcinoma and its relationship with prognosis[J]. Journal of Practical Hepatology, 2021, 24(1): 115-118.

References

[1] Christodoulou EG, Yang H, Lademann F, et al. Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens. Oncotarget, 2017, 8(21):34283-34297.
[2] Bulir DC, Waltho DA, StoneCB, et al. Chlamydia pneumoniae copd translocator protein plays a critical role in type III secretion (T3S) and infection. PLoS One, 2014, 9(6):e99315.
[3] Fields KA, Fischer ER, Mead DJ, et al. Analysis of putative chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates. J Bacteriol, 2005, 187(18):6466-6478.
[4] An C, Li H, Zhang X, et al. Silencing of COPB2 inhibits the proliferation of gastric cancer cells and induces apoptosis via suppression of the RTK signaling pathway. Int J Oncol, 2019, 54(4):1195-1208.
[5] Bhandari A, Zheng C, Sindan N, et al. COPB2 is up-regulated in breast cancer and plays a vital role in the metastasis via n-cadherin and vimentin. J Cell Mol Med, 2019, 23(8):5235-5245.
[6] Pu X, Wang J, Li W, et al. COPB2 promotes cell proliferation and tumorigenesis through up-regulating YAP1 expression in lung adenocarcinoma cells. Biomed Pharmacother, 2018, 103:373-380.
[7] Li ZS, Liu CH, Liu Z, et al. Downregulation of COPB2 by RNAi inhibits growth of human cholangiocellular carcinoma cells. Eur Rev Med Pharmacol Sci, 2018, 22(4):985-992.
[8] Zhou Y, Wang X, Huang X, et al. High expression of COPB2 predicts adverse outcomes: a potential therapeutic target for glioma. CNS Neurosci Ther, 2020 ,26(3):309-318.
[9] 代晓楠, 吕金燕, 翁文采, 等. 肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析. 实用肝脏病杂志, 2019, 22(1):117-120.
[10] Mak LY, Cruz-Ramón V, Chinchilla-López P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book, 2018, 23(38):262-279.
[11] Zhang B, Zhang B, Zhang Z, et al. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Sci China Life Sci, 2018, 61(6):660-670.
[12] Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis, 2015 ,19(2):421-432.
[13] Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int, 2019, 13(2):125-137.
[14] Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology, 2017, 93(Suppl 1):135-146.
[15] Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett, 2016, 379(2):191-197.
[16] Li D, Roberts R. Wd-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci, 2001, 58(14):2085-2097.
[17] Chen HL, Li JJ, Jiang F, et al. MicroRNA-4461 derived from bone marrow mesenchymal stem cell exosomes inhibits tumorigenesis by downregulating COPB2 expression in colorectal cancer. Biosci Biotechnol Biochem, 2020, 84(2):338-346.
[18] Sudo H, Tsuji AB, Sugyo A, et al. Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse mode. Genomics, 2010, 95(4):210-216.
[19] Wang Y, Chai Z, Wang M, et al. COPB2 suppresses cell proliferation and induces cell cycle arrest in human colon cancer by regulating cell cycle-related proteins. Exp Ther Med, 2018, 15(1):777-784.

Expression of copb2 gene incancerous tissues in patients with hepatocellular carcinoma and its relationship with prognosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xing Xiaoyan,Huang Liangmiao, Fu Aixian,et al.. Short-term observation of yinzhihuang and adenosine methionine in treatment of patients withintrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2020, 23(5): 670-673.
[2]	Wang Pei, Zhang Qing, Li Ying, et al.. Usefulness of red blood cell distribution width and neutrophil to lymphocyte ratio model for a short-term prognosis of patients with hepatitis B virus-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2020, 23(5): 682-686.
[3]	Han Pengwei, Wang Huming, Zhao Tianyong. Clinical feature and prognostic factors of primary liver cancer patients with serum AFP negative after TACE [J]. Journal of Practical Hepatology, 2020, 23(5): 715-718.
[4]	Lu Bin, Cheng Min.. Serum level of dickopff 1 in patients with hepatocellular carcinoma and its impact on prognosis after TACE treatment [J]. Journal of Practical Hepatology, 2020, 23(5): 719-722.
[5]	He Wenchang, Zhang Kegong, Zhao Fanhui, et al. Clinical feature of 290 patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2020, 23(4): 540-543.
[6]	Feng Tao, Hu Wei, Teng Buwei, et al. Value of ALBI and future liver remnant combinationin predicting the occurrence of post-hepatectomy liver failure in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2020, 23(4): 585-588.
[7]	Luo Ling, Deng Wanyu, Peng Lei, et al.. Preliminary study on therapeutic efficacy of plasma exchange in the treatment of patients with liver failure [J]. Journal of Practical Hepatology, 2020, 23(3): 384-387.
[8]	Cui Zhe,Xu Lan. Clinical significance of cancerous FAM49B gene in patients with hepatocellular carcinoma: an analysis based on multidatabase [J]. Journal of Practical Hepatology, 2020, 23(3): 413-418.
[9]	Wang Liangliang,Yang Bo,Zhang Weiguo. Comparison of fluorescent laparoscopic hepatectomy and conventional laparoscopic hepatectomy in the treatment of patients with HCC [J]. Journal of Practical Hepatology, 2020, 23(3): 427-430.
[10]	Wang Wei, Du Xiaofei, Lu Yunjian. Predicting value for survival by preoperative NLR of patients with massive hepatocellular carcinoma treated by TACE combined with MWA [J]. Journal of Practical Hepatology, 2020, 23(2): 260-263.
[11]	Li Tianzong, Zhou Song, Zhou Shi. Significance of blood miR-145 in patients with hepatocellular carcinoma after TACE treatment [J]. Journal of Practical Hepatology, 2020, 23(2): 264-267.
[12]	Hu Hong, Liao Yunguo, Wei Xin, et al. Clinical comparison of ¹²⁵I seed implantation or 3DCRT and TACE combination in treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2020, 23(2): 268-271.
[13]	Li Jia, Jiang Jiling, Huang Mengli, et al. Correlation of serumvascular endothelial growth factor-C and carcinoembryonic antigen levels to prognosis in patients with gallbladder cancer [J]. Journal of Practical Hepatology, 2020, 23(2): 284-287.
[14]	Liu Xiao, He Nian’an, Ye Xianjun, et al. Application of contrast-enhanced ultrasound in differential diagnosis of hepatocellular carcinoma and liver metastases [J]. Journal of Practical Hepatology, 2020, 23(1): 94-97.
[15]	Shi Yingying, Wang Yuanxi. Application of liver imaging report and data management system in diagnosis of hepatocellular carcinoma in CT and MR examinations [J]. Journal of Practical Hepatology, 2020, 23(1): 98-101.